Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US-2024101580-A1 · Mar 28, 2024 · US
Compositions and methods for treating cancer with aberrant lipogenic signaling
US9988403B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9988403-B2 |
| Application number | US-201715434454-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 16, 2017 |
| Priority date | Jun 25, 2012 |
| Publication date | Jun 5, 2018 |
| Grant date | Jun 5, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The technology described herein relates to dimethyl boronate esters of the following formula for the treatment of cancers expressing abnormally high levels of SREBP1:
First claim
Opening claim text (preview).
What is claimed herein is: 1. A compound selected from the group consisting of: 2. A pharmaceutical composition comprising a compound of claim 1 . 3. The composition of claim 2 , further comprising a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9988403B2 cover?
- The technology described herein relates to dimethyl boronate esters of the following formula for the treatment of cancers expressing abnormally high levels of SREBP1:
- Who is the assignee on this patent?
- Univ Jefferson
- What technology area does this patent fall under?
- Primary CPC classification C07F5/025. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).